A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

NCT07019883 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

NIH

Sponsor class

Conditions

Avian Influenza

Interventions

BIOLOGICAL: H5 AC-Anhui RNA Vaccine
BIOLOGICAL: H5 Astrakhan RNA Vaccine
OTHER: Sodium Chloride, 0.9%

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)